🧠 Cerebral Venous Sinus Thrombosis (CVST) Management
By whether hemorrhage is present and whether there is progressive deterioration, give anticoagulation, oral maintenance, endovascular/decompression and symptomatic direction. Instant, browser-side.
Clinical takeaway
Anticoagulation is the cornerstone even when a hemorrhagic infarct is present — the hemorrhage is from venous congestion and anticoagulation is proven safe.
Loading calculator…
Paste the link in Slack, Teams, X, or LinkedIn — the preview image comes from this page’s Open Graph card.
When to use
Management framing of cerebral venous sinus thrombosis.
How it works
Acute phase → therapeutic anticoagulation with LMWH (preferred over unfractionated), given even with hemorrhagic venous infarction. Transition to warfarin (INR 2–3) or a DOAC; duration provoked 3–6 mo, unprovoked 6–12 mo, recurrent/thrombophilia/cancer long-term. Deterioration despite full anticoagulation → endovascular therapy; herniation → decompressive craniectomy.
Key points
- Anticoagulation is the cornerstone even when a hemorrhagic infarct is present — the hemorrhage is from venous congestion and anticoagulation is proven safe.
- DOACs (dabigatran, apixaban/rivaroxaban) are non-inferior to warfarin; warfarin is preferred in antiphospholipid syndrome / active cancer / renal impairment.
- Manage raised ICP (acetazolamide, lumbar drainage/shunt for vision-threatening isolated intracranial hypertension) and seizures; steroids are not routinely used.
- Find and treat the trigger; women with prior CVST should avoid estrogen-progestin contraception.
References
Decision support for licensed clinicians only; not a substitute for clinical judgement, diagnosis or local protocols.
Worked calculation
The values below come from this tool's own example placeholders and are computed server-side with the formula shown on this page, so the arithmetic can be checked quickly. It demonstrates how to substitute values only — it is not clinical advice and not a real case.
| Concomitant hemorrhagic venous infarction | Yes |
|---|---|
| Progressive deterioration despite full anticoagulation / herniation | Yes |
→ActionAnticoagulation + endovascular/decompression assessment
- Anticoagulation (cornerstone)：Acute-phase therapeutic anticoagulation — low-molecular-weight heparin (preferred over unfractionated; use unfractionated in renal impairment or when urgent reversal/surgery may be needed); anticoagulate even with concomitant hemorrhagic venous infarction (CVST hemorrhage arises from venous congestion, so anticoagulation is the foundational treatment and is proven safe in randomised trials)
- Subsequent oral therapy：Transition to oral anticoagulation: vitamin K antagonist (warfarin INR 2–3) or a DOAC (dabigatran RE-SPECT CVT, apixaban/rivaroxaban ACTION-CVT, etc., non-inferior); duration — provoked 3–6 months, unprovoked 6–12 months, recurrent or definite thrombophilia/active cancer long-term; warfarin preferred in antiphospholipid syndrome/active cancer/renal impairment
- Progression/herniation：Severe cases with progressive deterioration despite full anticoagulation: consider endovascular therapy (mechanical thrombectomy/local thrombolysis; TO-ACT did not show a routine mortality benefit); parenchymal lesion with herniation → decompressive craniectomy as a life-saving measure
| Concomitant hemorrhagic venous infarction | No |
|---|---|
| Progressive deterioration despite full anticoagulation / herniation | No |
→ActionTherapeutic-dose anticoagulation
- Anticoagulation (cornerstone)：Acute-phase therapeutic anticoagulation — low-molecular-weight heparin (preferred over unfractionated; use unfractionated in renal impairment or when urgent reversal/surgery may be needed); anticoagulation is likewise the basis in patients without hemorrhage
- Subsequent oral therapy：Transition to oral anticoagulation: vitamin K antagonist (warfarin INR 2–3) or a DOAC (dabigatran RE-SPECT CVT, apixaban/rivaroxaban ACTION-CVT, etc., non-inferior); duration — provoked 3–6 months, unprovoked 6–12 months, recurrent or definite thrombophilia/active cancer long-term; warfarin preferred in antiphospholipid syndrome/active cancer/renal impairment
- Symptomatic：Raised intracranial pressure: acetazolamide, and if needed lumbar drainage or shunt (for isolated intracranial hypertension threatening vision); seizures: antiseizure drugs for supratentorial lesions or clinical seizures (not prophylactic); steroids not recommended (unless a concomitant inflammatory disease)
Frequently asked questions
- What is Cerebral Venous Sinus Thrombosis (CVST) Management?
- By whether hemorrhage is present and whether there is progressive deterioration, give anticoagulation, oral maintenance, endovascular/decompression and symptomatic direction. Instant, browser-side.
- How is Cerebral Venous Sinus Thrombosis (CVST) Management calculated? What is the core formula?
- Acute phase → therapeutic anticoagulation with LMWH (preferred over unfractionated), given even with hemorrhagic venous infarction. Transition to warfarin (INR 2–3) or a DOAC; duration provoked 3–6 mo, unprovoked 6–12 mo, recurrent/thrombophilia/cancer long-term. Deterioration despite full anticoagulation → endovascular therapy; herniation → decompressive craniectomy.
- When is Cerebral Venous Sinus Thrombosis (CVST) Management used?
- Management framing of cerebral venous sinus thrombosis.
- What are the key clinical points for Cerebral Venous Sinus Thrombosis (CVST) Management?
- Anticoagulation is the cornerstone even when a hemorrhagic infarct is present — the hemorrhage is from venous congestion and anticoagulation is proven safe. DOACs (dabigatran, apixaban/rivaroxaban) are non-inferior to warfarin; warfarin is preferred in antiphospholipid syndrome / active cancer / renal impairment. Manage raised ICP (acetazolamide, lumbar drainage/shunt for vision-threatening isolated intracranial hypertension) and seizures; steroids are not routinely used. Find and treat the trigger; women with prior CVST should avoid estrogen-progestin contraception.
- What are the limits and cautions when using Cerebral Venous Sinus Thrombosis (CVST) Management?
- For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.
- How is Cerebral Venous Sinus Thrombosis (CVST) Management calculated in practice? Can you show a worked example?
- Inputs: Concomitant hemorrhagic venous infarction Yes, Progressive deterioration despite full anticoagulation / herniation Yes → Result: Action Anticoagulation + endovascular/decompression assessment（Anticoagulation (cornerstone): Acute-phase therapeutic anticoagulation — low-molecular-weight heparin (preferred over unfractionated; use unfractionated in renal impairment or when urgent reversal/surgery may be needed); anticoagulate even with concomitant hemorrhagic venous infarction (CVST hemorrhage arises from venous congestion, so anticoagulation is the foundational treatment and is proven safe in randomised trials), Subsequent oral therapy: Transition to oral anticoagulation: vitamin K antagonist (warfarin INR 2–3) or a DOAC (dabigatran RE-SPECT CVT, apixaban/rivaroxaban ACTION-CVT, etc., non-inferior); duration — provoked 3–6 months, unprovoked 6–12 months, recurrent or definite thrombophilia/active cancer long-term; warfarin preferred in antiphospholipid syndrome/active cancer/renal impairment, Progression/herniation: Severe cases with progressive deterioration despite full anticoagulation: consider endovascular therapy (mechanical thrombectomy/local thrombolysis; TO-ACT did not show a routine mortality benefit); parenchymal lesion with herniation → decompressive craniectomy as a life-saving measure） Inputs: Concomitant hemorrhagic venous infarction No, Progressive deterioration despite full anticoagulation / herniation No → Result: Action Therapeutic-dose anticoagulation（Anticoagulation (cornerstone): Acute-phase therapeutic anticoagulation — low-molecular-weight heparin (preferred over unfractionated; use unfractionated in renal impairment or when urgent reversal/surgery may be needed); anticoagulation is likewise the basis in patients without hemorrhage, Subsequent oral therapy: Transition to oral anticoagulation: vitamin K antagonist (warfarin INR 2–3) or a DOAC (dabigatran RE-SPECT CVT, apixaban/rivaroxaban ACTION-CVT, etc., non-inferior); duration — provoked 3–6 months, unprovoked 6–12 months, recurrent or definite thrombophilia/active cancer long-term; warfarin preferred in antiphospholipid syndrome/active cancer/renal impairment, Symptomatic: Raised intracranial pressure: acetazolamide, and if needed lumbar drainage or shunt (for isolated intracranial hypertension threatening vision); seizures: antiseizure drugs for supratentorial lesions or clinical seizures (not prophylactic); steroids not recommended (unless a concomitant inflammatory disease)）